Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical studies.
Sickle cell community scrambles to find safe plan after a drug is pulled from the market
After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left scrambling to figure out what to do.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options,
Pfizer to Withdraw Sickle Cell Drug Oxbryta Lots from World-Wide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta. Pfizer said late on Wednesday it was pulling the drug from all markets due to risk of a painful complication and death.
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death
Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in patients with sickle cell disease. Guggenheim Securities analysts said the setback increases investor frustrations with the company’s business development track record.
Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. | Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide,
Pfizer withdraws sickle cell drug Oxbryta over safety concerns
Pfizer (PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety concerns. Read more here.
15h
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
4d
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
10h
Pfizer starts voluntary withdraw of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
devdiscourse
2d
Today’s Health Roundup: Schizophrenia Breakthrough and Bird Flu Vaccination Pressures
This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...
Yahoo Finance
3d
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
Pfizer PFE said it is withdrawing its sickle-cell drug (“SCD”) drug,
Oxbryta
from worldwide markets. Merck’s MRK Keytruda ...
STAT
3d
Biotech’s real estate market is still upside down
Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...
devdiscourse
3d
Major Developments in Health Sector: New Drugs and Global Initiatives
The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...
3d
European Union watchdog puts sickle cell disease drug on ice
European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Pfizer
Sickle Cell
Food and Drug Administration
Feedback